For more information call (888) LUHS-888.
Adult men with progressive castration-resistant metastatic prostate cancer who have not had treatment with prior taxane-based chemotherapy for their metastatic disease. They must not have any clinically significant cardiovascular disease or other major co-morbidities and have a PS 0-1.
The purpose of this study is to compare the effects, good and/or bad, of abiraterone, prednisone and enzalutamide with enzalutamide alone on you and your prostate cancer to find out which is better. Doctors are uncertain about what is the best way to treat castration-resistant prostate cancer.